PsyenceGroup

Psyence is a life science biotech company pioneering the use of natural psilocybin to heal psychologic trauma CSE: PSYG OTCQB: PSYGF

[PsyenceGroup @PsyenceGroup]

The investment from Cantheon Capital will help fund our first Phase IIb #clinicaltrial in Australia. It will go towards the design and conduct of our trial, using a natural #Psilocybin drug candidate PEX010, in the #PalliativeCare setting.
https://t.co/K1ljsu3fi2

[PsyenceGroup @PsyenceGroup]

iNGENu is an Australian CRO with extensive experience in the psychedelic pharma drug dev & clinical research industry. iNGENū will jointly design #Psyence's clinical trial, using a natural #psilocybin drug candidate PEX010, in the #palliativecare setting.

https://t.co/aGChleaDV9

[PsyenceGroup @PsyenceGroup]

We are thrilled to have been featured on the iconic
@Nasdaq tower in Times Square. This proposed transaction with Newcourt will enable us to execute our early-stage development program in #palliativecare. Congratulations to all at
@Psyence for making this happen.

[MindForward @mndfrwrd]

With contributions from @Awakn_ls $AWKN, @CybinInc $CYBN and @PsyenceGroup $PSYG, The Psychedelics as Medicine Report: Fourth Edition empowers investors to make informed decisions.

Download your complimentary copy today: https://t.co/xzJ7jBkfN2

[PsyenceGroup @PsyenceGroup]

@PsyenceGroup is one of the first companies to successfully export pharma grade #psilocybin into the UK, a market that has the potential to be a leader in #psychedelics research.

https://t.co/GyNUAwyoXs

[PsyenceGroup @PsyenceGroup]

@PsyenceGroup & Newcourt announce that Newcourt has entered into a definitive business combination agreement with Psyence Biomed, #Psyence's clinical trial division, to create a public company leveraging #psilocybin in the treatment of #palliativecare.

https://t.co/FhmOUORFtO

[PsyenceGroup @PsyenceGroup]

New year, new milestone for @PsyenceGroup as we announce our partnership with iNGENū CRO. #iNGENū will jointly design #Psyence's Phase IIb clinical trial, to be conducted in Australia. Read more here:
https://t.co/z2JwIWCjTY

[alastair moore @alastair_moore_]

Good to see @clerkenwell_uk's client @PsyenceGroup growing quickly. Really interesting palliative focus – an area that has interested me for a long time. https://t.co/3BXlx9aJJW

[PsyenceGroup @PsyenceGroup]

The investment in @PsyenceGroup by a member of the Kerzner family, one of South Africa’s most recognised family offices, will be used to advance our #palliativecare #clinicaltrial, drug development programme and our ISO22000 production facility.

https://t.co/gPK6yvQgpk

[PsyenceGroup @PsyenceGroup]

@FNBSA is the banking app down?

[PsyenceGroup @PsyenceGroup]

Alberta to be 1st province to regulate psychedelics for therapy. An incredibly important move - we are excited to watch this space. https://t.co/MJzJsTa0nz

[PsyenceGroup @PsyenceGroup]

Congratulations to our team at Psyence who ensured another successful export of our #psilocybin mushrooms for medical research purposes. The mushrooms were delivered to Psilo Pharma Inc. in Portugal.
https://t.co/myTYKNniBw

[Stockhouse Publishing @stockhouse]

Psyence Group (CSE:PSYG) named first mover into palliative care market https://t.co/LnI8PonehK @PsyenceGroup #CSE: $PSYG #stockmarket #trading

[Stockhouse Publishing @stockhouse]

Psyence Group (#CSE: $PSYG) receives Phase IIa clinical trial approval from the UK MHRA https://t.co/lwZBLXTlXI @PsyenceGroup #markets #ThePowerPlay

[Psychedelic Finance @Psych_Fin]

News: Psyence Group | $PSYG $PSYGF

Successfully exported psilocybin mushrooms to Psilo Scientific, a wholly owned subsidiary of $FH.

@PsyenceGroup operates one of the first federally licensed commercial psilocybin production facilities in the world.

https://t.co/kZSh3h0fqS

[The Armchair Trader @armchairtweets]

We caught up with the management team at Psyence Group $PSYG just ahead of their announced Phase II trials in the UK

@PsyenceGroup
https://t.co/12EDIkQcK7

[PsyenceGroup @PsyenceGroup]

Another milestone @PsyenceGroup, we exported #psilocybin mushrooms to Psilo Scientific, subsidiary of @FilamentHealth. This is on target with our goal to be a commercial supplier of psilocybin mushrooms for the legal, global medical and research market.

https://t.co/UcWp1tBeT1

[PsyenceGroup @PsyenceGroup]

Independent research by Hannam & Partners notes the significance of the #MHRA's approval of #Psyence's Phase 2 study exploring the therapeutic potential of #psilocybin for the treatment of #neuropsychiatric diseases. The report can be found here:
https://t.co/3yXbPsiUGW

[PsyenceGroup @PsyenceGroup]

⁦@PsyenceGroup announces we have⁩ received MHRA approval for our Phase IIa clinical trial in the context of #palliativecare - to be conducted in the UK with ⁦@clerkenwell_uk⁩ https://t.co/OdvyU57WBj

[PsyenceGroup @PsyenceGroup]

@PsyenceGroup is developing innovative, safe and effective #psychedelic and nature-centred solutions for mental health and #PalliativeCare. We are focussed on natural #psilocybin, which we cultivate at our ISO22000 certified facility. Visit https://t.co/Tfn5uqW6hI to learn more.